KR20220044811A - Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기 - Google Patents

Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기 Download PDF

Info

Publication number
KR20220044811A
KR20220044811A KR1020227008026A KR20227008026A KR20220044811A KR 20220044811 A KR20220044811 A KR 20220044811A KR 1020227008026 A KR1020227008026 A KR 1020227008026A KR 20227008026 A KR20227008026 A KR 20227008026A KR 20220044811 A KR20220044811 A KR 20220044811A
Authority
KR
South Korea
Prior art keywords
lys
trans
leu
glu
splicing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227008026A
Other languages
English (en)
Korean (ko)
Inventor
제이콥 보라조
Original Assignee
메사추세츠 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메사추세츠 인스티튜트 오브 테크놀로지 filed Critical 메사추세츠 인스티튜트 오브 테크놀로지
Publication of KR20220044811A publication Critical patent/KR20220044811A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227008026A 2019-08-16 2020-08-14 Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기 Ceased KR20220044811A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962888210P 2019-08-16 2019-08-16
US62/888,210 2019-08-16
US202062985633P 2020-03-05 2020-03-05
US62/985,633 2020-03-05
PCT/US2020/046523 WO2021034717A1 (en) 2019-08-16 2020-08-14 Targeted trans-splicing using crispr/cas13

Publications (1)

Publication Number Publication Date
KR20220044811A true KR20220044811A (ko) 2022-04-11

Family

ID=72291120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008026A Ceased KR20220044811A (ko) 2019-08-16 2020-08-14 Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기

Country Status (8)

Country Link
US (3) US11767528B2 (https=)
EP (1) EP4013873A1 (https=)
JP (1) JP2022544688A (https=)
KR (1) KR20220044811A (https=)
CN (1) CN115023499A (https=)
AU (1) AU2020333667A1 (https=)
CA (1) CA3150747A1 (https=)
WO (1) WO2021034717A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277987A4 (en) * 2021-02-25 2025-07-16 Univ Duke COMPOSITIONS AND METHODS FOR TRANSCRIPTOME ENGINEERING
WO2022187524A1 (en) * 2021-03-05 2022-09-09 The Jackson Laboratory Multiplex rna targeting
WO2022266849A1 (zh) * 2021-06-22 2022-12-29 中国科学院脑科学与智能技术卓越创新中心 新型CRISPR-Cas13蛋白的筛选及其应用
EP4141112B1 (en) * 2021-07-08 2025-06-11 Korea Advanced Institute of Science and Technology Rna expression regulation or editing method through activity control of cas13 protein
AU2022337146A1 (en) 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components
AU2022343271A1 (en) * 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Recruitment in trans of gene editing system components
EP4404953A4 (en) * 2021-09-21 2025-09-24 Univ Johns Hopkins MRNA REGULATORY THERAPY FOR THE TREATMENT OF HAPLOINSUFFICIENCY DISORDERS
US20240409920A1 (en) * 2021-10-15 2024-12-12 The Broad Institute, Inc. Rna-guided trans-splicing of rna
EP4522758A4 (en) 2022-05-13 2026-05-06 Ascidian Therapeutics Inc Abca4 trans-splicing molecules
CA3265828A1 (en) * 2022-08-25 2024-02-29 Massachusetts Institute Of Technology PROGRAMMABLE RNA WRITING USING CRISPR EFFECTORS AND TRANS-SPLICING MODELS
WO2024112957A1 (en) 2022-11-23 2024-05-30 Amber Bio Inc. Gene-modifying endonucleases
US20250151704A1 (en) * 2023-11-10 2025-05-15 Joseph Fenton Lawler Trans-splicing methods and compositions for generation of single sex offspring
WO2026068725A1 (en) * 2024-09-26 2026-04-02 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Synthetic transfer vehicles for delivering rna to cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US7868149B2 (en) 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US6603061B1 (en) 1999-07-29 2003-08-05 Monsanto Company Agrobacterium-mediated plant transformation method
GB0024550D0 (https=) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
EP2151248A1 (en) * 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011148194A1 (en) 2010-05-28 2011-12-01 Oxford Biomedica (Uk) Ltd Delivery of lentiviral vectors to the brain
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
SG2014012207A (en) * 2011-08-12 2014-05-29 Virxsys Corp Compositions and methods for inducing apoptosis
WO2014110509A1 (en) * 2013-01-14 2014-07-17 Cellecta, Inc. Methods and compositions for single cell expression profiling
US20190330620A1 (en) 2016-10-14 2019-10-31 Emendobio Inc. Rna compositions for genome editing
EP3617311B1 (en) * 2017-03-30 2024-11-20 Kyoto University Method for inducing exon skipping by genome editing
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions

Also Published As

Publication number Publication date
EP4013873A1 (en) 2022-06-22
US20240035031A1 (en) 2024-02-01
WO2021034717A1 (en) 2021-02-25
US11767528B2 (en) 2023-09-26
AU2020333667A1 (en) 2022-02-24
CN115023499A (zh) 2022-09-06
JP2022544688A (ja) 2022-10-20
US12297433B2 (en) 2025-05-13
US20250236872A1 (en) 2025-07-24
US20210071178A1 (en) 2021-03-11
CA3150747A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
AU2018240515B2 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
US12565666B2 (en) Methods and compositions for modulating a genome
AU2022200673B2 (en) Compositions and methods for degradation of misfolded proteins
AU2018338787B2 (en) Compositions and methods for TTR gene editing and treating ATTR amyloidosis
KR20220113442A (ko) 입자 전달 시스템
KR20230057487A (ko) 게놈 조정을 위한 방법 및 조성물
AU2014259755B2 (en) Compositions and methods for modulating apolipoprotein (a) expression
KR20200116933A (ko) 인간 심근세포에서 디스트로핀 돌연변이를 교정하기 위한 조성물 및 방법
KR20190072548A (ko) Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
KR20250028508A (ko) 큐론을 포함하는 조성물 및 그의 용도
KR20200126997A (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
AU2014338859B2 (en) Phage therapy of Pseudomonas infections
KR20230046313A (ko) 다중에피토프 백신 카세트
KR20210060429A (ko) 적응 면역의 조절을 위한 조성물 및 방법
KR20210131309A (ko) 분비형 치료 양식을 운반하기 위한 아넬로좀
KR20210125990A (ko) 단백질 대체 치료 양식을 운반하기 위한 아넬로좀
KR20210131310A (ko) 아넬로좀 및 사용 방법
KR20230129162A (ko) 제1형 근긴장성 이영양증을 치료하기 위한 rna 표적화조성물 및 방법
KR20210082205A (ko) 레트로바이러스 인테그라제-Cas9 융합 단백질을 이용한 유도된 비상동 DNA 삽입에 의한 게놈 편집
KR20230127221A (ko) Cag 반복 질환을 치료하기 위한 rna 표적화 조성물및 방법
CN113874512A (zh) 诱导毛细胞分化的组合物和方法
CN114945666A (zh) 用于rna分子高效重组的组合物和方法
KR20180092989A (ko) 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
KR20210131308A (ko) 세포내 치료 양식을 운반하기 위한 아넬로좀

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601